Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
Levine
Glenn N
GN
D'Amico
Anthony V
AV
Berger
Peter
P
Clark
Peter E
PE
Eckel
Robert H
RH
Keating
Nancy L
NL
Milani
Richard V
RV
Sagalowsky
Arthur I
AI
Smith
Matthew R
MR
Zakai
Neil
N
D026683:Advisory Committees; D000570:American Cancer Society; D000572:American Heart Association; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D012955:Societies, Medical; D014481:United States
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone